Fig. 3

Association between HERVK9 expression and prognosis of AML cases with 3 + 7-based intensive chemotherapy. (a) Case selection flowchart for survival analyses. Detailed patient information from TCGA-LAML is available in Supplemental Table S10. (b) Determination of the optimal cutoff value for HERVK9-derived ORF expression for log-rank analysis using maxillary selected rank statistics in 90 AML cases. (c) EFS curves of AML cases stratified by HERVK9 expression levels. (d) EFS curves of AML cases stratified by both HERVK9 expression levels and NCCN2017 risk classification. (e) Genomic localization of HERVK9-derived ORFs on chromosome 19 (red square). (f) Reverse transcription polymerase chain reaction analyses of two annotated DE-EVEs shown in (e)ACTB was used as an internal control